Formulary evaluation of targeted oncology therapies: pharmaceutics and therapeutics workflow insights from a Pacific Northwest health system
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/brfm7187 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Amlan Barik. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Development of targeted therapies and advancements in protein biomarker analysis have facilitated better prognosis for some cancer disease states and resulted in the reevaluation of treatment pathways, with biomarker testing now critical for guiding therapy. With the evaluation of clinical studies and subsequent Food and Drug Administration (FDA) approval of Biologics License Applications (BLAs) for targeted therapies to fulfill the unmet needs of managing therapy gaps, targeted therapies are constantly requested by clinicians for addition to formularies as some targeted anticancer drugs offer more manageable side effect profiles and higher efficacy in specific cancer disease states. While providers can use non-formulary medications for specific disease states, an in-depth and multi-faceted review of each new targeted anticancer medication is needed prior to a Pharmaceutics and Therapeutics (P&T) meeting for approval of a medication to a formulary. This ultimately increases the likelihood of targeted therapies reaching patients that need them most.
Zitieren
APA
Barik, A. (2026). Formulary evaluation of targeted oncology therapies: pharmaceutics and therapeutics workflow insights from a Pacific Northwest health system. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/brfm7187
Vancouver
Barik A. Formulary evaluation of targeted oncology therapies: pharmaceutics and therapeutics workflow insights from a Pacific Northwest health system. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/brfm7187
BibTeX
@article{Barik2026,
author = {Barik, Amlan},
title = {Formulary evaluation of targeted oncology therapies: pharmaceutics and therapeutics workflow insights from a Pacific Northwest health system},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/brfm7187}
}
EUVIMED